No internet connection — showing the saved version of the page.

UNITED THERAPEUTI…

USUSD
← to the screener

UNITED THERAPEUTICS Corp (US:UTHR) — Biotechnology: Pharmaceutical Preparations. Number of exchanges where the company shares trade: 1. On this page — price and chart, dividends, top holders and share count history.

About the company

Website
unither.com
Investor relations
ir.unither.com/
Sector
Health Care · Biotechnology: Pharmaceutical Preparations
Headquarters
SILVER SPRING, United States
Management
Martine A. Rothblatt
Latest reports
quarterly 2026 · 10-Q for the period ended 2026-03-31
Employees
1 400
Shares outstanding
42.59 M as of 2026-10-28
DateSharesChange
28.10.202642.59 M−0.7%buyback
29.07.202642.89 M
Share count from the company reports. A split is detected by a jump in the count by a whole number of times.
Free float
39.21 M
Market cap
25.46 B USD
Insiders
2%
Institutions
100.29%
Industry (SIC)
Pharmaceutical Preparations
P/E
21.8
EPS
26.49 USD
P/B
3.94
ROE
19.1%
FCF
867 M USD
Debt
3.70 M USD
net cash
Earnings and FCF — for the 12 months to 30.09.2026 (the company's latest report).
Net income
1.23 B USD 12 mo.
For the 12 months to 30.09.2026 (4 quarters)
Revenue3.19 B USD
− Expenses1.87 B USD
Gross profit2.75 B USD
Net income1.23 B USD
History by quarter
RevenueExpenses
31.12.2023: Revenue 615 M · Expenses 355 M · Operating profit 260 M · Net income 217 M31.03.2024: Revenue 678 M · Expenses 321 M · Operating profit 356 M · Net income 307 M30.06.2024: Revenue 715 M · Expenses 395 M · Operating profit 320 M · Net income 278 M30.09.2024: Revenue 749 M · Expenses 406 M · Operating profit 343 M · Net income 309 M31.12.2024: Revenue 736 M · Expenses 378 M · Operating profit 358 M · Net income 301 M31.03.2025: Revenue 794 M · Expenses 412 M · Operating profit 383 M · Net income 322 M30.06.2025: Revenue 799 M · Expenses 434 M · Operating profit 365 M · Net income 310 M30.09.2025: Revenue 800 M · Expenses 411 M · Operating profit 389 M · Net income 339 M31.12.2025: Revenue 790 M · Expenses 434 M · Operating profit 357 M · Net income 364 M31.03.2026: Revenue 782 M · Expenses 456 M · Operating profit 326 M · Net income 275 M30.06.2026: Revenue 783 M · Expenses 453 M · Operating profit 331 M · Net income 333 M30.09.2026: Revenue 833 M · Expenses 525 M · Operating profit 308 M · Net income 259 M
12.202309.2026
Green above orange is profit (revenue − expenses); red below zero is a loss.
NAV
148 USD · P/NAV 3.90
Balance sheet date30.09.2026
Assets7.03 B USD
− Liabilities758 M USD
= NAV (equity of the company's shareholders)6.28 B USD
= Tangible NAV6.28 B USD
Shares42 382 126
NAV per share148 USD
Tangible NAV per share148 USD
Share price (UTHR)577.34 USD
P/NAV3.90
NAV history
Balance sheet dateNAVNAV per share
30.09.20266.28 B USD148 USD
30.06.20266.40 B USD150 USD
31.03.20265.90 B USD140 USD
31.12.20257.10 B USD163 USD
30.09.20256.59 B USD154 USD
30.06.20257.17 B USD159 USD
31.03.20256.81 B USD151 USD
31.12.20246.44 B USD144 USD
Description

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

advertisement

Exchanges and tickers

ExchangeTickerCurrencyPriceType
common stock
US USA StocksUTHRUSD577.34 -1.16%common stock
depositary receipt
SA B3 Sao PauloU2TH34BRL127 +0.00%depositary receipt

Price

US:UTHR · USD
Hover / tap a day — open, close, high and low prices

Top holders

HolderStakeSharesReport date
Blackrock Inc.12.34%5.29 M2026-06-30
Avoro Capital Advisors L…6.48%2.78 M2026-06-30
Vanguard Portfolio Manag…4.48%1.92 M2026-06-30
Vanguard Capital Managem…4.47%1.92 M2026-06-30
State Street Corporation4.43%1.9 M2026-06-30
Renaissance Technologies…3.98%1.71 M2026-06-30
iShares Trust-iShares Co…3.56%1.53 M2026-09-30
Wellington Management Gr…3.22%1.38 M2026-06-30
VANGUARD INDEX FUNDS-Van…3.14%1.35 M2026-06-30
Geode Capital Management…2.32%996 5982026-06-30
VANGUARD INDEX FUNDS-Van…2.27%973 4902026-06-30
Jupiter Topco LLC1.94%831 1292026-06-30
VANGUARD SPECIALIZED FUN…1.68%719 3852026-07-31
NORGES BANK1.62%694 7532026-06-30
VANGUARD INDEX FUNDS-Van…1.13%486 5552026-06-30
iShares Trust-iShares Bi…0.75%323 4322026-09-30
SPDR S&P MIDCAP 400 ETF…0.74%317 1342026-09-30
VANGUARD INDEX FUNDS-Van…0.72%308 3282026-06-30
VANGUARD WORLD FUND-Vang…0.71%304 1302026-05-31
Invesco Exchange-Traded…0.69%296 3252026-09-30
MAHON PAUL A (General Co…≈0.11%45 1722026-10-01
THOMPSON TOMMY G (Direct…≈0.05%22 4802026-03-26
GILTNER RICHARD A (Direc…≈0.05%21 8842026-07-09
EDGEMOND JAMES C. (Chief…≈0.04%18 8762026-06-22
KURZWEIL RAYMOND C (Dire…≈0.03%13 3202026-07-09
MESA NILDA (Director)≈0.01%5 5802026-09-14
OLIAN JUDY D. (Director)≈0.01%5 5552026-07-09
CAUSEY CHRISTOPHER (Dire…≈0.01%4 1902026-03-30
BENKOWITZ MICHAEL (Presi…——2026-03-13
ROTHBLATT MARTINE A (Chi…——2026-10-27